Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of ...
ascopubs.org

A single-arm, exploratory study of disitamab vedotin (DV) combined with camrelizumab and platinum-based chemotherapy as first-line treatment in patients with HER2 expressing ...

LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET+) NSCLC. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A Global Summit for ...

Tattoo ink moves through the body, killing immune cells and weakening vaccine response

Tattoo ink doesn’t just sit inertly in the skin. New research shows it moves rapidly into the lymphatic system, where it can ...
ascopubs.org

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial

Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial Standard-of-care first-line treatment ...
Medical Dialogues

Medical Bulletin 29/November/2025 - Video

New research links tattoos to increased melanoma skin cancer risk Tattoos might seem like harmless self-expression, but could they secretly raise your ...